Company Galena Biopharma Inc Nasdaq

Equities

US3632561086

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Mar. 28	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Managers	Title	Age	Since
Angelos Stergiou FOU	Founder	48	06-04-02
John Burns DFI	Director of Finance/CFO	39	13-04-30
Andrew Elnatan LAW	General Counsel	-	23-01-04
Dragan Cicic PRN	Corporate Officer/Principal	60	20-02-09

Members of the board	Title	Age	Since
Robert van Nostrand BRD	Director/Board Member	67	17-12-28
David Scheinberg BRD	Director/Board Member	68	17-11-30
John Varian BRD	Director/Board Member	64	17-12-28
Jane Wasman CHM	Chairman	67	17-12-28
Angelos Stergiou FOU	Founder	48	06-04-02
Katherine Kalin BRD	Director/Board Member	61	22-08-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	56,267,670	55,984,386 ( 99.50 %)	0	99.50 %

Name	Equities	%	Valuation
Highbridge Capital Management LLC 3.697 %	2,080,054	3.697 %	2 M $
Vanguard Global Advisers LLC 2.039 %	1,147,324	2.039 %	1 M $
Armistice Capital LLC 1.457 %	820,000	1.457 %	828 200 $
BlackRock Institutional Trust Co. NA 0.4879 %	274,552	0.4879 %	277 298 $
Geode Capital Management LLC 0.4365 %	245,603	0.4365 %	248 059 $
Group One Trading LP 0.3312 %	186,355	0.3312 %	188 219 $
Angelos Stergiou 0.3120 %	175,546	0.3120 %	177 301 $
Equitable Advisors LLC 0.2932 %	165,000	0.2932 %	166 650 $
Opus Capital Group LLC 0.2399 %	135,000	0.2399 %	136 350 $
STATE STREET CORPORATION 0.1726 %	97,129	0.1726 %	98 100 $

SELLAS Life Sciences Group, Inc.

Times Square Tower 7 Times Square

10026, New York

http://www.sellaslifesciences.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B

Bio Therapeutic Drugs